このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

全般性不安障害におけるMM120をプラセボと比較して評価する非盲検延長試験(パートB)を伴う第3相二重盲検プラセボ対照試験(パートA)

2026年9月24日 更新者:Definium Therapeutics US, Inc.

フェーズ 3、多施設共同、無作為化、二重盲検、プラセボ対照、12 週間の試験 (パート A) と 40 週間の非盲検延長 (パート B) でプラセボと比較した経口 MM120 の有効性と安全性を評価する全般性不安障害の成人の治療 - Voyage

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

The study will enroll up to 200 participants aged 18 to 74 years, inclusive with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) confirmed primary diagnosis of GAD and a minimum HAM-A total score of at least 20 at Screening and Baseline without clinically relevant medical or psychiatric history.

The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating DT120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment. During this phase, participants will be monitored and evaluated for potential treatment with DT120 based on pre-specified safety and symptom severity criteria.

研究の種類

介入

入学 (実際)

214

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Gilbert、Arizona、アメリカ、85234
        • Lighthouse Psychiatry
      • Scottsdale、Arizona、アメリカ、85022
        • Scottsdale Research Institute
    • California
      • La Jolla、California、アメリカ、92037
        • Kadima Neuropsychiatry Institute
      • San Francisco、California、アメリカ、94158
        • UCSF Department of Neurology
      • Santa Monica、California、アメリカ、90404
        • Psychedelic Science Institute
    • Colorado
      • Denver、Colorado、アメリカ、80209
        • Mountain View
    • Florida
      • Jacksonville、Florida、アメリカ、32256
        • Clinical Neuroscience Solutions Inc.
      • Lauderhill、Florida、アメリカ、33319
        • Segal Trials
    • Georgia
      • Atlanta、Georgia、アメリカ、30331
        • Atlanta Center for Medical Research
      • Decatur、Georgia、アメリカ、30030
        • iResearch Atlanta
      • Savannah、Georgia、アメリカ、31405
        • CenExel iResearch, LLC
    • Illinois
      • Chicago、Illinois、アメリカ、60640
        • Uptown Research Institute
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02116
        • Adams Clinical Boston
      • Watertown、Massachusetts、アメリカ、02472
        • Adams Clinical Watertown
    • New Jersey
      • Marlton、New Jersey、アメリカ、08053
        • Hassman Research Institute
    • New York
      • New York、New York、アメリカ、10021
        • Spectrum Neuroscience and Treatment Institute
      • New York、New York、アメリカ、10032
        • New York State Psychiatric Institute (NYSPI)
      • New York、New York、アメリカ、10029
        • Adams Clinical Harlem
      • The Bronx、New York、アメリカ、10461
        • Adams Clinical Bronx
    • Ohio
      • Cleveland、Ohio、アメリカ、44113
        • Cleveland Clinic Lutheran Hospital
    • Oregon
      • Portland、Oregon、アメリカ、97210
        • Summit Headlands LLC
    • Pennsylvania
      • Moosic、Pennsylvania、アメリカ、18507
        • Scranton Medical Institute
      • Philadelphia、Pennsylvania、アメリカ、19104
        • Adams Clinical Philadelphia
    • South Carolina
      • North Charleston、South Carolina、アメリカ、29405
        • Coastal Carolina Research Center
    • Tennessee
      • Memphis、Tennessee、アメリカ、38119
        • Clinical Neuroscience Solutions, Inc.
    • Texas
      • Austin、Texas、アメリカ、78712
        • University of Texas at Austin
      • Austin、Texas、アメリカ、78759
        • BioBehavioral Research of Austin
      • Austin、Texas、アメリカ、78737
        • Austin Clinical Trial Partners
      • Dallas、Texas、アメリカ、75231
        • FutureSearch Trials of Dallas, LLC
      • DeSoto、Texas、アメリカ、75115
        • Adams Clinical Dallas
    • Utah
      • Draper、Utah、アメリカ、84020
        • Cedar Clinical Research
      • Orem、Utah、アメリカ、84058
        • Inner Space Research
    • Vermont
      • Bennington、Vermont、アメリカ、05201
        • Memory Clinic Inc.
    • Washington
      • Seattle、Washington、アメリカ、98104
        • Seattle Neuropsychiatric Treatment Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~74年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Diagnosis of GAD per DSM-5
  2. Male or female aged 18 to 74
  3. HAM-A Total Score ≥20

Exclusion Criteria:

  1. Certain psychiatric disorders (other than generalized anxiety disorder)
  2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
  3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
  4. Any clinically significant unstable illness

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:Arm 1 - Placebo

A substance that is designed to have no therapeutic value

A substance that is designed to have no therapeutic value

実験的:Arm 2 - 100µg DT120

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

他の名前:
  • 酒石酸リセルグ酸
  • MM120
  • LSD D-Tartrate

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12
時間枠:Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Clinical Global Impression - Improvement (CGI-I) Scale score at each timepoint assessed during the 12-week double-blind period
時間枠:Day 2 to Week 12

The CGI-I scale is used to measure the clinician's assessment of how much the participant's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises one item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening.

Day 2 to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
時間枠:Baseline to Week 12

The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
時間枠:Baseline to Week 12

The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)
時間枠:Baseline to Week 12

The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS).

Baseline to Week 12
Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period
時間枠:Baseline to Week 12

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

Baseline to Week 12
Percent of men and women with normal and abnormal sexual functioning at each timepoint assessed during the double-blind period
時間枠:Baseline to Week 12

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

Baseline to Week 12
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in MADRS total score
時間枠:Baseline to Week 52

The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
時間枠:Baseline to Week 52

The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
時間枠:Baseline to Week 52

The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in WPAI-SHP
時間枠:Baseline to Week 52

The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in EQ-5D-5L
時間枠:Baseline to Week 52

The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS).

Baseline to Week 52
Percent men and women with normal and abnormal sexual functioning at each timepoint assessed during the open-label period
時間枠:40 week open label period

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

40 week open label period
Change from Baseline in HAM-A total score at Week 8, Week 4, Week 2, and Week 1
時間枠:Week 8, Week 4, Week 2, and Week 1

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Week 8, Week 4, Week 2, and Week 1
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period
時間枠:Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12
HAM-A remission (total score ≤7) at each timepoint assessed during the 12-week double-blind treatment period
時間枠:Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score
時間枠:Baseline to Week 12

The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in -Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)
時間枠:Baseline to Week 12

The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study.

Baseline to Week 12
Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period
時間枠:Day 1 to Week 52

Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period

Day 1 to Week 52
Time to first treatment or lack of efficacy in the open-label period (Part B)
時間枠:Day 1 to Week 52

Measured as time from first dosing in the Double-blind period to participant meeting HAM-A criteria for re-dose or meeting criteria for lack of efficacy

Day 1 to Week 52
Need for DT120 treatment as assessed by the average number of DT120 treatments during the study
時間枠:Day 1 to Week 52

Average number of treatments assessed from first dose in the double-blind period through completion of the open label extension.

Day 1 to Week 52
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 40-week open-label period
時間枠:40 week open label period

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

40 week open label period
HAM-A remission (total score ≤7) at each timepoint assessed during the 40-week open-label period
時間枠:40 week open label period

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

40 week open label period
CSFQ-14 total score at each timepoint assessed during the open-label period
時間枠:40 week open label period

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

40 week open label period

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年12月11日

一次修了 (実際)

2026年7月15日

研究の完了 (推定)

2027年4月1日

試験登録日

最初に提出

2024年12月16日

QC基準を満たした最初の提出物

2024年12月16日

最初の投稿 (実際)

2024年12月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月25日

QC基準を満たした最後の更新が送信されました

2026年9月24日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • MM120-300

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。